IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	: 10/797,609
Applicant	: Laurence J.N. COOPER et al.
Filed	: March 11, 2004
TC/A.U.	: 1646
Examiner	: To Be Assigned
Docket No.	: 1954-417
Customer No.	: 06449
Confirmation No.	: 4062

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449.

Respectfully submitted,

By _____

Martha Cassidy
Attorney for Applicants
Registration No. 44,066
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

Enclosure(s):
PTO-1449 Forms
References

1954-417.ids.wpd

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Complete if Known
Application Number	10/797,609
Filing Date	March 11, 2004
First Named Inventor	Laurence J.N. Cooper et al.
Group Art Unit	1646
Examiner Name	To Be Assigned
Sheet 1 of 3	Attorney Docket Number 1954-417

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	1.	Yee, C. et al., "Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: *in vivo* persistence, migration, and antitumor effect of transferred T cells," *Proc. Natl. Acad. Sci. U.S.A.* 99 (25):16168-16173, 2002.	
	2.	Dudley, M.E. et al. "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes," *Science* 298:850-854, 2002.	
	3.	Brodie, S.J. et al., "HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death," *J. Clin. Invest.* 105(10):1407-417, 2000.	
	4.	Wang, R.F. et al., "Human tumor antigens for cancer vaccine development," *Immunol. Rev.* 170:85-100, 1999.	
	5.	Pardoll, D. "Does the immune system see tumors as foreign or self?" *Annu. Rev. Immunol.* 21:807-839, 2003.	
	6.	Garrido, F. et al., "MHC antigens and tumor escape from immune surveillance," *Adv. Cancer Res.* 83:117-158, 2001.	
	7.	Pule, M. et al., "Artificial T-cell receptors," *Cytotherapy* 5(3):211-226, 2003.	
	8.	Jensen, M.C. et al., "Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy," *Cytotherapy* 5(2):131-138, 2003.	
	9.	Sadelain, M. et al., "Targeting tumours with genetically enhanced T lymphocytes," *Nat. Rev. Cancer* 3:35-45, 2003.	
	10.	Lupton, S.D. et al., "Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene," *Mol. Cell. Biol.* 11(6):3374-3378, 1991.	
	11.	Ho, S.N. et al., "Site-directed mutagenesis by overlap extension using the polymerase chain reaction," *Gene* 77:51-59, 1989.	
	12.	Gotch, F. et al., "Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2," *Nature* 326:881-882, 1987.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/797,609
				Filing Date	March 11, 2004
				First Named Inventor	Laurence J.N. Cooper et al.
				Group Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	2	of	3	Attorney Docket Number	1954-417

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	13.	Larsson, M. et al., "Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells," *J. Immunol.* 165:1182-1190, 2000.	
	14.	Morrison, J. et al., "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes," *Eur. J. Immunol.* 22:903-907, 1992.	
	15.	Gross, Gideon, et al., "Endowing T cells with antibody specificity using chimeric T cell receptors," *The FASEB Journal* 6:3370-3378, 1992.	
	16.	Heslop, Helen E., et al., "Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes," *Nature Medicine* 2(5):551-555, 1996.	
	17.	Walter, Elizabeth A., et al., "Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor," *The New England Journal of Medicine* 333:1038-44, 1995.	
	18.	Rossig, Claudia, et al., "Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy," *Blood* 99(6):2009-2016, 2002.	
	19.	Brocker, Thomas, "Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells," *Blood* 96(5):1999-2001, 2000.	
	20.	Brocker, Thomas, and Klaus Karjalainen, "Signals through T Cell Receptor-ζ Chain Alone Are Insufficient to Prime Resting T Lymphocytes," *J. Exp. Med.* 181:1653-1659, 1995.	
	21.	Nel, Andre E., "T-cell activation through the antigen receptor. Part 1: Signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse," *J. Allergy Clin. Immunol.* 109:758-70, 2002.	
	22.	Gotch, F. et al., "Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site," *J. Exp. Med.* 168:2045-2057, 1988.	
	23.	Latron, F. et al., "Positioning of a peptide in the cleft of HLA-A2 by complementing amino acid changes," *Proc. Natl. Acad. Sci. U.S.A.* 88:11325-11329, 1991.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code. [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/797,609
				Filing Date	March 11, 2004
				First Named Inventor	Laurence J.N. Cooper et al.
				Group Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	3	of	3	Attorney Docket Number	1954-417

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	24.	Stewart-Jones, G.B. et al., "A structural basis for immunodominant human T cell receptor recognition," *Nat. Immunol.* 4(7):657-63, 2003.	
	25.	Schultze, J. et al., "B7-mediated costimulation and the immune response," *Blood Rev.* 10:111-127, 1996.	
	26.	Young, J.W. et al., "The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation," *Stem Cells* 14:376-387, 1996.	
	27.	Lehner, P.J. et al., "Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment," *J. Exp. Med.* 181:79-91, 1995.	
	28.	Lawson, T.M. et al., "Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses," *Int. Immunol.* 13(11):1373-1381, 2001.	
	29.	Moss, P.A. et al., "Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide," *Proc. Natl. Acad. Sci. U.S.A.* 88:8987-8990, 1991.	
	30.	Krummel, M.F. et al., "Dynamics of the immunological synapse: finding, establishing and solidifying a connection," *Curr. Opin. Immunol.* 14:66-74, 2002.	
	31.	Rojo, J.M. et al., "Physical association of CD4 and the T-cell receptor can be induced by anti-T-cell receptor antibodies," *Proc. Natl. Acad. Sci. U.S.A.* 86:3311-3315, 1989.	
	32.	Kershaw, M.H. et al., "Dual-specific T cells combine proliferation and antitumor activity," *Nat. Biotechnol.* 20:1221-1227, 2002.	
	33.	Roessig, C. et al., "Targeting CD19 with genetically modified EBV-specific human T lymphocytes," *Ann. Hematol.* 81(Suppl 2):S42-3, 2002.	
	34.	Ahn, J.H. et al., "Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis," *Blood* 100:1742-1754, 2002.	
	35.	Uetsuki, T. et al., "Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha," *J. Biol. Chem.* 264(10):5791-5798, 1989.	
	36.	Mahmoud, M.S. et al., "Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity," *Blood* 94(10):3551-3558, 1999.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]Applicant is to place a check mark here if English language Translation is attached.